Astellas Pharma (ALPMY) Stock Price, News & Analysis

Company Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Key Stats

• Today's Range: $9.84 to $10.41
• 50-Day Range: $8.84 to $10.15
• 52-Week Range: $8.37 to $13.14
• Volume: 94,047 shs
• Average Volume: 217,695 shs
• Market Capitalization: $18.37 billion
• P/E Ratio: N/A
• Dividend Yield: 3.25%
• Price Target: N/A
• Consensus Rating: N/A

ALPMY Stock Analysis - Frequently Asked Questions

How have ALPMY shares performed this year?

Astellas Pharma's stock was trading at $9.66 at the beginning of 2025. Since then, ALPMY stock has increased by 5.1% and is now trading at $10.15.
View the best growth stocks for 2025 here.

How were Astellas Pharma's earnings last quarter?

Astellas Pharma Inc. (OTCMKTS:ALPMY) released its quarterly earnings results on Friday, April, 25th. The company reported $0.27 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.12. The company had revenue of $3.22 billion for the quarter, compared to analyst estimates of $3.02 billion. Astellas Pharma had a positive trailing twelve-month return on equity of 13.69% and a negative net margin of 3.10%.

When did Astellas Pharma's stock split?

Astellas Pharma shares split on the morning of Wednesday, April 2nd 2014. The 5-4 split was announced on Friday, March 14th 2014. The newly minted shares were issued to shareholders after the closing bell on Tuesday, April 1st 2014. An investor that had 100 shares of stock prior to the split would have 125 shares after the split.

Does Astellas Pharma have any subsidiaries?

Astellas Pharma subsidiaries include Iota Biosciences, Nanna Therapeutics, Xyphos, Audentes Therapeutics, Potenza Therapeutics, Quethera, Universal Cells Inc., and more.

How do I buy shares of Astellas Pharma?

Shares of ALPMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/25/2025
• Today: 5/06/2025
• Fiscal Year End: 3/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:ALPMY
• CIK: 1446390
• Web: www.astellas.com
• Phone: (133) 244-3000
• Fax: N/A
• Employees: 14,754
• Year Founded: 1923

Profitability

• EPS (Most Recent Fiscal Year): $0.17
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 24.17
• P/E Growth: N/A
• Net Income: $113 million
• Net Margins: -3.10%
• Pretax Margin: N/A
• Return on Equity: 13.69%
• Return on Assets: 6.06%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 1.04
• Quick Ratio: 0.80

Sales & Book Value

• Annual Sales: $11.11 billion
• Price / Sales: 1.65
• Cash Flow: $1.21 per share
• Price / Cash Flow: 8.42
• Book Value: $5.84 per share
• Price / Book: 1.74

Miscellaneous

• Outstanding Shares: 1,809,660,000
• Free Float: N/A
• Market Cap: $18.37 billion
• Optionable: Not Optionable
• Beta: 0.31